Rahul Pal
Overview
Explore the profile of Rahul Pal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal R, Pandey P, Chawra H, Khan Z
Pharm Nanotechnol
. 2025 Mar;
PMID: 40059418
Background: Tuberculosis (TB) and chronic pain are global health concerns that affect millions of people, often requiring long-term, effective treatment strategies. The conventional therapies used to manage these conditions come...
2.
Pal R, Krishnamoorthy M, Matsui A, Kang H, Morita S, Taniguchi H, et al.
Cancer Res
. 2024 Nov;
85(3):618-632.
PMID: 39514403
Patient selection for cancer immunotherapy requires precise, quantitative readouts of biomarker expression in intact tumors that can be reliably compared across multiple subjects over time. The current clinical standard biomarker...
3.
Gupta S, Pal R, Schmidt E, Krishnamoorthy M, Leporati A, Kumar A, et al.
iScience
. 2024 Aug;
27(8):110102.
PMID: 39184438
Clinical imaging-assisted oncosurgical navigation requires cancer-specific miniaturized optical imaging probes. We report a near-infrared (NIR) Fab'-based epidermal growth factor receptor (EGFR)-specific probe carrying 3 NIR fluorophores (Fab'-800CW), which retained high-affinity...
4.
Galhotra A, Rathore V, Pal R, Nayak S, Ramasamy S, Patel S, et al.
Indian J Nephrol
. 2024 Aug;
34(3):241-245.
PMID: 39114396
Background: Chronic kidney disease (CKD) not associated with known risk factors, called CKD of unknown etiology (CKDu), has been reported from several geographically distinct regions across the world. This study...
5.
Pal R, Talwar S, Pandey M, Nain V, Sharma T, Tyagi S, et al.
Tuberculosis (Edinb)
. 2024 Jan;
145:102477.
PMID: 38211498
Mycobacterium tuberculosis (Mtb) has evolved sophisticated surveillance mechanisms to neutralize the ROS-induces toxicity which otherwise would degrade a variety of biological molecules including proteins, nucleic acids and lipids. In the...
6.
Pal R, K M, Matsui A, Kang H, Morita S, Taniguchi H, et al.
Res Sq
. 2023 Nov;
PMID: 37961361
Cancer patient selection for immunotherapy is often based on programmed death-ligand-1 (PD-L1) expression as a biomarker. PD-L1 expression is currently quantified using immunohistochemistry, which can only provide snapshots of PD-L1...
7.
Pal R, Lwin T, Krishnamoorthy M, Collins H, Chan C, Prilutskiy A, et al.
Nat Biomed Eng
. 2023 Oct;
7(12):1649-1666.
PMID: 37845517
The surgical resection of solid tumours can be enhanced by fluorescence-guided imaging. However, variable tumour uptake and incomplete clearance of fluorescent dyes reduces the accuracy of distinguishing tumour from normal...
8.
Pandey M, Talwar S, Pal R, Nain V, Johri S, Singhal A, et al.
Res Microbiol
. 2023 May;
174(7):104082.
PMID: 37244349
Transcription factors (TFs) of Mycobacterium tuberculosis (Mtb), an etiological agent of tuberculosis, regulate a network of pathways that help prolong the survival of Mtb inside the host. In this study,...
9.
Sarkar M, Singh P, Pal R
STAR Protoc
. 2023 Apr;
4(2):102242.
PMID: 37099429
Beta-hCG is associated with poor patient prognosis in several cancers, but the particular pathophysiology of beta-hCG in post-menopausal women remains unaddressed. Specific steps to culture Lewis lung carcinoma (LLC1) tumor...
10.
Villarreal P, Pal R, Qiu S, Coblens O, Villasante-Tezanos A, Resto V, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831646
Depth-resolved label-free optical imaging by the method of multiphoton autofluorescence microscopy (MPAM) may offer new ways to examine cellular and extracellular atypia associated with epithelial squamous cell carcinoma (SCC). MPAM...